{"id":81511,"date":"2026-05-04T17:45:29","date_gmt":"2026-05-04T12:15:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=81511"},"modified":"2026-05-04T17:45:32","modified_gmt":"2026-05-04T12:15:32","slug":"epigral-q4-results-fy26","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/","title":{"rendered":"Epigral Q4 Results FY26 Record Revenue Rs 736 Crore EBITDA Margin 23 Percent"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p>Epigral Q4 results for FY26 marked a record quarter for India&#8217;s leading chlorine derivatives and specialty chemicals manufacturer. Revenue hit Rs 736 crore, up 17% year on year, the highest quarterly revenue in the company&#8217;s history. The Epigral Q4 results were supported by strong demand for CPVC resin, chloromethanes, and downstream derivatives from domestic and export markets.<\/p>\n<p>The Epigral Q4 results FY26 also demonstrated robust profitability with PAT at Rs 82 crore and an EBITDA margin of 23%, reflecting healthy realisations and operational efficiency in its integrated chlor-alkali complex. The Epigral Q4 results board declared a dividend of Rs 5 per share for FY26, a signal of strong cash flows.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Stock Recommendations on Univest<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#Epigral_Q4_FY26_Results_at_a_Glance\" title=\"Epigral Q4 FY26 Results at a Glance\">Epigral Q4 FY26 Results at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#Key_Highlights_from_Epigral_Q4_FY26_Results\" title=\"Key Highlights from Epigral Q4 FY26 Results\">Key Highlights from Epigral Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#Record_Revenue_Milestone_for_Epigral\" title=\"Record Revenue Milestone for Epigral\">Record Revenue Milestone for Epigral<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#EBITDA_Margin_at_23_Percent_in_Q4_FY26\" title=\"EBITDA Margin at 23 Percent in Q4 FY26\">EBITDA Margin at 23 Percent in Q4 FY26<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#What_Drove_Epigral_Q4_FY26_Performance\" title=\"What Drove Epigral Q4 FY26 Performance\">What Drove Epigral Q4 FY26 Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#Dividend_and_Shareholder_Returns\" title=\"Dividend and Shareholder Returns\">Dividend and Shareholder Returns<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#Outlook_for_FY27\" title=\"Outlook for FY27\">Outlook for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#What_was_Epigral_Q4_FY26_revenue\" title=\"What was Epigral Q4 FY26 revenue?\">What was Epigral Q4 FY26 revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#What_is_Epigral_EBITDA_margin_in_Q4_FY26\" title=\"What is Epigral EBITDA margin in Q4 FY26?\">What is Epigral EBITDA margin in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#What_dividend_did_Epigral_declare_for_FY26\" title=\"What dividend did Epigral declare for FY26?\">What dividend did Epigral declare for FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#What_products_drive_Epigral_revenue\" title=\"What products drive Epigral revenue?\">What products drive Epigral revenue?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/epigral-q4-results-fy26\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Epigral_Q4_FY26_Results_at_a_Glance\"><\/span><strong>Epigral Q4 FY26 Results at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Change \/ Context<\/th>\n<\/tr>\n<tr>\n<td>Revenue<\/td>\n<td>Rs 736 crore<\/td>\n<td>+17% YoY, record quarter<\/td>\n<\/tr>\n<tr>\n<td>Net Profit PAT<\/td>\n<td>Rs 82 crore<\/td>\n<td>Strong profitability<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margin<\/td>\n<td>23%<\/td>\n<td>Healthy realisations<\/td>\n<\/tr>\n<tr>\n<td>Dividend<\/td>\n<td>Rs 5 per share<\/td>\n<td>FY26 payout<\/td>\n<\/tr>\n<tr>\n<td>CPVC Resin Sales<\/td>\n<td>Growing volumes<\/td>\n<td>Key product<\/td>\n<\/tr>\n<tr>\n<td>Export Contribution<\/td>\n<td>Meaningful<\/td>\n<td>Diversified revenue<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Track live Epigral financials, analyst ratings and peer comparisons on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Highlights_from_Epigral_Q4_FY26_Results\"><\/span><strong>Key Highlights from Epigral Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Record_Revenue_Milestone_for_Epigral\"><\/span><strong>Record Revenue Milestone for Epigral<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Epigral Q4 results FY26 reported revenue of Rs 736 crore, up 17% year on year, the highest quarterly revenue in the company&#8217;s history. The Epigral Q4 results milestone was driven by strong domestic demand from the construction and water treatment sectors alongside growing export shipments of chloromethanes and CPVC resin, confirming the company&#8217;s scaling trajectory.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"EBITDA_Margin_at_23_Percent_in_Q4_FY26\"><\/span><strong>EBITDA Margin at 23 Percent in Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>EBITDA margin in the Epigral Q4 results FY26 came in at 23%, reflecting healthy caustic soda and CPVC resin realisations. The integrated chlor-alkali model provides Epigral with a natural cost hedge. The Epigral Q4 results show that margin management has improved significantly and the company is sustaining profitability through the full product cycle.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Drove_Epigral_Q4_FY26_Performance\"><\/span><strong>What Drove Epigral Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Epigral Q4 results were driven by healthy pricing for CPVC resin, sustained chloromethane demand from pharmaceutical and refrigerant sectors, and caustic soda demand from alumina and textile industries. The company&#8217;s expanding downstream product portfolio reduces reliance on any single commodity cycle, a key theme in the Epigral Q4 results over recent years. This diversification supports earnings stability.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_and_Shareholder_Returns\"><\/span><strong>Dividend and Shareholder Returns<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Epigral declared a dividend of Rs 5 per share for FY26 as part of the Epigral Q4 results announcement. The company&#8217;s strong free cash flow generation from its integrated chemical operations enables a consistent dividend policy while also funding capacity expansion projects that will support future revenue growth beyond the Epigral Q4 results FY26 base.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Outlook_for_FY27\"><\/span><strong>Outlook for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following the Epigral Q4 results FY26, the company is well-positioned for continued growth in FY27. New capacity in ECU and downstream derivatives is expected to come onstream progressively. The Epigral Q4 results management commentary indicates that EBITDA margins are expected to sustain in the 22 to 24% range as realisation environment remains supportive.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Epigral Q4 results FY26 delivered a record-breaking quarter with revenue at Rs 736 crore up 17%, PAT at Rs 82 crore, EBITDA margin at 23%, and a dividend of Rs 5 per share. The Epigral Q4 results FY26 confirm the company&#8217;s strength as India&#8217;s leading integrated chlor-alkali and specialty chemicals manufacturer. FY27 new capacity additions and stable downstream realisations make the Epigral Q4 results a strong foundation for continued growth.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest Android App<\/strong><\/a> for live Q4 results tracking and expert research.<\/p>\n<p><em>Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Epigral_Q4_FY26_revenue\"><\/span><strong>What was Epigral Q4 FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Epigral Q4 results FY26 showed record revenue of Rs 736 crore, up 17% year on year, driven by CPVC resin, chloromethanes, and caustic soda demand from domestic and export markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Epigral_EBITDA_margin_in_Q4_FY26\"><\/span><strong>What is Epigral EBITDA margin in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>EBITDA margin in Epigral Q4 results FY26 was 23%, reflecting healthy product realisations and the cost efficiency of its integrated chlor-alkali manufacturing complex in Gujarat.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_dividend_did_Epigral_declare_for_FY26\"><\/span><strong>What dividend did Epigral declare for FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Epigral declared a dividend of Rs 5 per share for FY26, reflecting strong cash flow generation from its chemicals business as highlighted in the Epigral Q4 results FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_products_drive_Epigral_revenue\"><\/span><strong>What products drive Epigral revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Epigral Q4 results FY26 revenue was driven by CPVC resin, chloromethanes, caustic soda, and other chlorine derivatives used in construction, pharma, and industrial sectors.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-nuvoco-share-price-falling-key-reasons-2026\">Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-capacite-share-price-falling-key-reasons-2026\">Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-psp-projects-share-price-falling-key-reasons-2026\">Why Is PSP Projects Share Price Falling Key Reasons 2026<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Epigral Q4 results FY26 show record revenue at Rs 736 crore up 17% YoY with PAT at Rs 82 crore and EBITDA margin of 23%. Dividend declared at Rs 5 per share for FY26.<\/p>\n","protected":false},"author":28,"featured_media":81572,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858,3983],"class_list":["post-81511","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results","tag-q4-results-2026"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1777896944:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Epigral Q4 Results FY26 Record Revenue Rs 736 Crore EBITDA Margin 23 Percent"],"rank_math_description":["Epigral Q4 results FY26: Record revenue Rs 736 crore up 17%, PAT Rs 82 crore, EBITDA margin 23%, dividend Rs 5. Chlorine derivatives analysis and FY27 outlook."],"rank_math_focus_keyword":["Epigral Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["81572"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10179"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/04174501\/Epigral-Q4-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/81511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=81511"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/81511\/revisions"}],"predecessor-version":[{"id":81574,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/81511\/revisions\/81574"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/81572"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=81511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=81511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=81511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}